Jeng-Shiuan Tsai
Overview
Explore the profile of Jeng-Shiuan Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang H, Kuo W, Tu P, Lee C, Wang H, Huang Y, et al.
ACS Nano
. 2025 Feb;
19(8):7634-7649.
PMID: 39965088
Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), a rapidly progressing respiratory failure condition, results in a high mortality rate, especially in severe cases. Numerous trials have investigated various pharmacotherapy...
2.
Kuo C, Lin C, Wei S, Chou Y, Chen C, Tsai J, et al.
Ther Adv Med Oncol
. 2023 Sep;
15:17588359231198454.
PMID: 37720497
Background: Invasive pulmonary aspergillosis (IPA) can negatively impact cancer patients' survival. It remains uncertain whether IPA's impact on patient outcomes varies by treatment approach in advanced lung cancer. Objectives: To...
3.
Chen C, Lin C, Tsai J, Lin C, Chang C, Yen Y, et al.
Front Oncol
. 2023 Sep;
13:1238876.
PMID: 37671055
Although combination therapy including chemotherapy and immune checkpoint inhibitors (ICIs) improves overall survival (OS) of patients with non-small-cell lung cancer (NSCLC), there is a higher incidence of adverse events and...
4.
Kuo C, Su P, Huang T, Lin C, Chen C, Tsai J, et al.
Sci Rep
. 2023 May;
13(1):7894.
PMID: 37193781
Alveolar macrophages (AMs) are the drivers of pulmonary cytokine storm in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This study aimed to investigate clinical-regulatory factors for the entrance protein...
5.
Lin C, Hu C, Hsu C, Tsai J, Chen C, Lin C, et al.
Thorac Cancer
. 2023 May;
14(19):1857-1864.
PMID: 37183851
Background: Some prospective studies have shown that second-generation tyrosine kinase inhibitors (TKIs) provide better control in patients with non-small cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR)...
6.
Chu C, Lin C, Lin C, Li C, Wu S, Tsai J, et al.
Sci Rep
. 2023 Mar;
13(1):3943.
PMID: 36894581
The role of Programmed Cell Death Ligand 1 (PD-L1) expression in predicting epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) efficacy remains controversial. Recent studies have highlighted that tumor-intrinsic PD-L1...
7.
Tsai J, Wei S, Chen C, Yang S, Tseng Y, Su P, et al.
Pharmaceuticals (Basel)
. 2022 Nov;
15(11).
PMID: 36422537
The use of immune checkpoint inhibitors (ICIs) has provided overall survival (OS) benefits in patients with treatment-naïve advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. However, studies comparing...
8.
Su P, Chen J, Chu C, Chen Y, Chen W, Lin K, et al.
Sci Rep
. 2022 Mar;
12(1):3319.
PMID: 35228655
Neoadjuvant immunotherapy and chemotherapy have improved the major pathological response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC). This study aimed to assess whether the presence of...
9.
Su P, Tsai J, Yang S, Wu Y, Tseng Y, Chang C, et al.
Lung Cancer
. 2021 Jul;
158:137-145.
PMID: 34214933
Objectives: Osimertinib is the main treatment choice for pretreated patients with advanced non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) T790M mutations. However, the choice of subsequent...
10.
Tsai J, Su P, Yang S, Chang C, Lin C, Yen Y, et al.
J Formos Med Assoc
. 2021 Apr;
120(9):1729-1739.
PMID: 33865672
Background: Recent study showed that the combination of erlotinib and bevacizumab had better disease control than erlotinib monotherapy in patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung...